Nanotechnological Carriers for Treatment of Acne.

Q3 Medicine

Recent patents on anti-infective drug discovery Pub Date : 2018-01-01 DOI:10.2174/1574891X13666180918114349

Shivani Verma, Puneet Utreja, Lalit Kumar

{"title":"Nanotechnological Carriers for Treatment of Acne.","authors":"Shivani Verma, Puneet Utreja, Lalit Kumar","doi":"10.2174/1574891X13666180918114349","DOIUrl":null,"url":null,"abstract":"Background: Acne is a multifactorial skin disease associated with pilosebaceous unit and caused by bacteria Propionibacterium acnes and Acne vulgaris. Near about 95% people throughout the world suffer from acne at some point in their life span. This disease is more prominent in adults compared to neonates and prepubescent children. Conventionally it is treated with either creams or gels having large number of side effects on patients.Methods: We searched about recent advancements in the use of nanotechnological carriers for effective treatment of acne. We focused on the use of liposomes, niosomes, microemulsions, microsponge, microspheres, and nanoparticles to improve anti-acne therapy. Patents regarding use of nanocarrier systems to eliminate acne were also discussed in this review.Results: The encapsulation of anti-acne drugs in various nanotechnological carriers improve their efficacy and reduce side effects. These carriers show controlled drug release and improved drug penetration even upto pilosebaceous unit of skin. Local tolerability of anti-acne molecules can be improved by adjusting the concentration in nanotechnological carriers.Conclusions: Nanotechnological carriers have opened a new window to design novel, effective and low dose systems for effective eradication acne disease. However, very few nanocarrier based formulations are available in market for topical use and much progress is required in this field to improve anti-acne therapy.","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on anti-infective drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574891X13666180918114349","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 10

Abstract

Background: Acne is a multifactorial skin disease associated with pilosebaceous unit and caused by bacteria Propionibacterium acnes and Acne vulgaris. Near about 95% people throughout the world suffer from acne at some point in their life span. This disease is more prominent in adults compared to neonates and prepubescent children. Conventionally it is treated with either creams or gels having large number of side effects on patients.

Methods: We searched about recent advancements in the use of nanotechnological carriers for effective treatment of acne. We focused on the use of liposomes, niosomes, microemulsions, microsponge, microspheres, and nanoparticles to improve anti-acne therapy. Patents regarding use of nanocarrier systems to eliminate acne were also discussed in this review.

Results: The encapsulation of anti-acne drugs in various nanotechnological carriers improve their efficacy and reduce side effects. These carriers show controlled drug release and improved drug penetration even upto pilosebaceous unit of skin. Local tolerability of anti-acne molecules can be improved by adjusting the concentration in nanotechnological carriers.

Conclusions: Nanotechnological carriers have opened a new window to design novel, effective and low dose systems for effective eradication acne disease. However, very few nanocarrier based formulations are available in market for topical use and much progress is required in this field to improve anti-acne therapy.

查看原文本刊更多论文

纳米技术载体治疗痤疮。

背景:痤疮是一种与毛囊皮脂腺单位相关的多因素皮肤病，由痤疮丙酸杆菌和寻常痤疮引起。全世界大约95%的人在一生中的某个阶段都患有痤疮。与新生儿和青春期前儿童相比，这种疾病在成人中更为突出。传统上，它是用药膏或凝胶治疗的，对病人有很大的副作用。方法:我们检索了纳米技术载体在有效治疗痤疮方面的最新进展。我们专注于使用脂质体、乳质体、微乳液、微海绵、微球和纳米颗粒来改善抗痤疮治疗。本综述还讨论了有关纳米载体系统用于消除痤疮的专利。结果:将抗痤疮药物包封在各种纳米载体中，提高了抗痤疮药物的疗效，减少了副作用。这些载体表现出药物释放控制和药物渗透改善，甚至达到皮肤毛囊皮脂腺单位。通过调节抗痤疮分子在纳米载体中的浓度，可以提高抗痤疮分子的局部耐受性。结论:纳米技术载体为设计新颖、有效、低剂量的痤疮疾病根除系统打开了一扇新的窗口。然而，市场上很少有基于纳米载体的配方可用于局部使用，这一领域需要取得很大进展，以改善抗痤疮治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Recent patents on anti-infective drug discovery Medicine-Pharmacology (medical)

CiteScore

2.40

自引率

0.00%

发文量

期刊介绍： Recent Patents on Anti-Infective Drug Discovery publishes review articles on recent patents in the field of anti-infective drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-infective drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-infective drug design and discovery.